The nation of Zimbabwe has turned down a significant American health deal valued at $367m (£272m) spanning five years due to Washington's demand for confidential information.
This move was revealed following a internal memorandum from December was leaked, revealing that Head of State Emmerson Mnangagwa believed the deal was "skewed".
An official representative later stated that the US was demanding access to genetic material for research and profit while refused to guarantee the benefits from future treatments.
"We are forced to start the difficult and regrettable process of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further negotiations to secure a deal agreeable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Background
This development comes after a similar situation in Kenya, where a court suspended a related deal with the US following concerns were filed about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral agreements to boost openness and accountability.
As per reports, Sixteen nations in Africa have to date agreed to similar agreements, representing more than $18.3bn in committed funds.
Specifics of the Declined Agreement
The money for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on antiretroviral therapy through American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to share its biological resources and data over an extended period, without any equivalent assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"Put simply, our nation would provide the raw materials for medical research without any assurance that the resulting innovations would be available to our population if a future pandemic emerge."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its push of bilateral deals were upending structures already set up via the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to deal with potential global health emergencies.
"This framework is designed to guarantee that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage ongoing dialogue with our American counterparts on how future collaboration could be designed in a way that respects the sovereignty and dignity of both nations."
Medical Community Response
Medical experts expressed it understood the government's concerns, but urged that talks must proceed since a large portion of the country's Aids initiatives relied on foreign aid.
"Where specific concerns exist, including those involving information security or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," it commented.
This impasse underscores the continuing challenges between receiving much-needed foreign assistance and protecting national sovereignty in an ever more data-driven world.